Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | EEF2K | O00418 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30008966 | 0.86 | THRB (0.69) | HDAC1HDAC2HDAC3THRBKMT2A | |
| SCHEMBL30008791 | 0.84 | EEF2K (0.69) | HDAC1HDAC2HDAC3THRBKMT2A | |
| SCHEMBL21480715 | 0.83 | HDAC1 (0.50) | HDAC1HDAC2HDAC3THRBKMT2A | |
| SCHEMBL18379857 | 0.83 | HDAC2 (1.00) | HDAC1HDAC2HDAC3KMT2A | |
| SCHEMBL13833393 | 0.82 | HDAC2 (0.65) | HDAC1HDAC2 | |
| SCHEMBL19860010 | 0.82 | RAB9A (0.71) | HDAC1HDAC2HDAC3THRBKMT2A | |
| SCHEMBL13833355 | 0.81 | TAS1R3 (0.80) | HDAC1HDAC2KMT2ATAS1R3TAS1R1 | |
| SCHEMBL30986004 | 0.81 | RAB9A (0.74) | HDAC1HDAC2HDAC3THRBKMT2A | |
| SCHEMBL13833390 | 0.80 | HDAC2 (1.00) | HDAC1HDAC2HDAC3 | |
| SCHEMBL914192 | 0.79 | HDAC1 (0.57) | HDAC1HDAC2HDAC3KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAc Therapeutics, Inc. | 2021-06-17 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190216754-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAC THERAPEUTICS INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-9365498-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| EP-2701699-A1 | INHIBITORS OF HISTONE DEACETYLASE | The Broad Institute, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149540-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE INC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149540-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE INC (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | HDAC1 2/4885HDAC2 4/4885HDAC3 1/4885 |
| US-10662199-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-20190216754-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | HDAC1 2/4885HDAC2 4/4885HDAC3 1/4885 |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.